Pool Vitali, Mege Larissa, Abou-Ali Adel
Sanofi Pasteur Inc., Discovery Drive, Swiftwater, PA 18370, USA.
Sanofi Pasteur SA, 14 Espace Henry Vallée, 69007 Lyon, France.
Vaccines (Basel). 2020 Jul 14;8(3):385. doi: 10.3390/vaccines8030385.
Repeat administration of tetanus toxoid-containing vaccines has rarely been associated with Arthus phenomenon, an immune-complex reaction. In the US, since 2013, tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccines (Tdap) have been recommended for administration during each pregnancy. Separately, in 2019, one Tdap was approved for repeat administration in adults in the US. We aimed to describe trends in spontaneously reported Arthus reactions following Tdap in the US and to assess the risk of this phenomenon in persons receiving Tdap repeatedly. We reviewed Arthus reports in the Vaccine Adverse Events Reporting System (VAERS), 1990-2018. Reporting rates were estimated using Tdap doses distributed data. A systematic literature review was conducted in MEDLINE for any Arthus cases reported in Tdap clinical trials and observational studies published between 2000 and 2019. We found 192 Arthus reports in VAERS after any vaccine, of which 36 occurred after Tdap and none were reported during pregnancy. The Arthus reporting rate was estimated at 0.1 per million doses distributed. We identified eight published studies of Tdap administration within five years after a previous dose of tetanus toxoid-containing vaccine; no Arthus cases were reported. We conclude that Arthus reaction following Tdap is extremely rare. Increasing frequency of repeat Tdap administration in adults in the US did not result in a detectable increase in reporting rates of this phenomenon, confirming the favorable safety profile of Tdap.
重复接种含破伤风类毒素疫苗很少与阿瑟斯现象(一种免疫复合物反应)相关。在美国,自2013年以来,破伤风类毒素、减毒白喉类毒素和无细胞百日咳疫苗(Tdap)被推荐在每次怀孕期间接种。另外,2019年,一种Tdap在美国被批准用于成人重复接种。我们旨在描述美国接种Tdap后自发报告的阿瑟斯反应趋势,并评估反复接种Tdap人群中出现这种现象的风险。我们回顾了1990 - 2018年疫苗不良事件报告系统(VAERS)中的阿瑟斯报告。报告率使用已分发的Tdap剂量数据进行估算。在MEDLINE中对2000年至2019年发表的Tdap临床试验和观察性研究中报告的任何阿瑟斯病例进行了系统的文献综述。我们在VAERS中发现了192例接种任何疫苗后的阿瑟斯报告,其中36例发生在接种Tdap后,且孕期无人报告。阿瑟斯报告率估计为每百万剂分发量中有0.1例。我们确定了八项关于在先前接种含破伤风类毒素疫苗后五年内接种Tdap的已发表研究;未报告阿瑟斯病例。我们得出结论,接种Tdap后的阿瑟斯反应极为罕见。美国成人中重复接种Tdap的频率增加并未导致该现象报告率出现可检测到的上升,证实了Tdap良好的安全性。